cell profiling strategy and unbiased genomic classification, together with follow-up profiling and functional and phenotypic characterization of prospectively isolated subsets, led us to identify and validate six DC subtypes and four monocyte subtypes, and thus revise the taxonomy of these cells.
RESULTS: Our study reveals: 1) A new DC subset, representing 2 to 3% of the DC populations across all 10 donors tested, characterized by the expression of AXL, SIGLEC1, and SIGLEC6 antigens, named AS DCs. The AS DC population further divides into two populations captured in the traditionally defined plasmacytoid DC (pDC) and CD1C + conventional DC (cDC) gates. This split is further reflected through AS DC gene expression signatures spanning a spectrum between cDC-like and pDClike gene sets. Although AS DCs share properties with pDCs, they more potently activate T cells. This discovery led us to reclassify pDCs as the originally described "natural interferonproducing cells (IPCs)" with weaker T cell proliferation induction ability.
2) A new subdivision within the CD1C + DC subset: one defined by a major histocompatibility complex class II-like gene set and one by a CD14 + monocyte-like prominent gene set. These CD1C + DC subsets, which can be enriched by combining CD1C with CD32B, CD36, and CD163 antigens, can both potently induce T cell proliferation.
3) The existence of a circulating and dividing cDC progenitor giving rise to CD1C + and CLEC9A + DCs through in vitro differentiation assays. This blood precursor is defined by the expression of CD100 + CD34 int and observed at a frequency of 0.02% of the LIN -HLA-DR + fraction. 4) Two additional monocyte populations: one expressing classical monocyte genes and cytotoxic genes, and the other with unknown functions.
5) Evidence for a relationship between blastic plasmacytoid DC neoplasia (BPDCN) cells and healthy DCs.
CONCLUSION: Our revised taxonomy will enable more accurate functional and developmental analyses as well as immune monitoring in health and disease. The discovery of AS DCs within the traditionally defined pDC population explains many of the cDC properties previously assigned to pDCs, highlighting the need to revisit the definition of pDCs. Furthermore, the discovery of blood cDC progenitors represents a new therapeutic target readily accessible in the bloodstream for manipulation, as well as a new source for better in vitro DC generation. Although the current results focus on DCs and monocytes, a similar strategy can be applied to build a comprehensive human immune cell atlas. (1) (2) (3) . DCs are heterogeneous and consist of multiple subtypes with unique functions that have been defined over the past decade in mice and humans. However, it is unclear how many DC subtypes exist, how they are related to each other, and how they differ from other mononuclear phagocytes.
Atlas of human blood dendritic cells and monocytes
Numerous studies have shown that human dendritic cells express high levels of major histocompatibility complex (MHC) class II (HLA-DR), a molecule essential for antigen presentation, and lack key markers of T cells, B cells, natural killer (NK) cells, granulocytes, and monocytes. In the blood, DC subtypes include CD11C + conventional DCs (cDCs), consisting of either CD141 + or CD1C + cells, and plasmacytoid DCs (pDCs), consisting of CD123 + cells. cDCs are effective at antigen-specific stimulation of CD4 + and CD8 + T cells, whereas pDCs specialize in producing type I interferons in response to viruses. pDCs and cDC subtypes differ in their expression of numerous sensors, pathways, and effectors, and play distinct roles in the immune response (1-3). The different DC subtypes have historically been defined by a combination of morphology, physical properties, localization, molecular markers, functions, and developmental origins, converging to the current model described above (1) (2) (3) . However, the definition of DCs is still likely to be biased by the limited markers available to identify, isolate, and manipulate the cells. Such biases, in turn, would alter the assignment of function and ontogeny to each DC subtype.
To overcome some of these limitations, we used single-cell RNA sequencing (scRNA-seq) (4, 5) to better assess the diversity of blood DCs and monocytes, leading us to identify new subtypes of DCs and monocytes, refine their existing classification, and pinpoint a precursor of cDCs in the blood. Using discriminative markers associated with the newly defined DC subtypes, we also assessed the functions of some of the DC subtypes. Overall, our analysis provides a relatively unbiased and comprehensive map of human blood DCs and monocytes.
Strategy for discovery and validation of DC and monocyte subtypes
To determine the subtypes of DCs and monocytes in human blood, we developed an experimental and computational strategy to (i) perform single-cell RNA sequencing on DCs and monocytes derived from a single healthy individual; (ii) identify clusters of cells that are similar to each other; (iii) find discriminative markers per cluster; (iv) prospectively isolate cells corresponding to key clusters using newly identified surface markers; (v) validate the identity of the sorted cells using scRNA-seq; (vi) confirm the existence of these cell types in up to 10 independent healthy individuals; and (vii) perform functional analyses for selected cell types.
Single-cell profiling of blood DCs and monocytes
We analyzed blood DC and monocyte populations from Ficoll-enriched cells that were isolated by fluorescence-activated cell sorting (FACS) (Fig. 1A) excluding cells expressing markers of B, T, and NK cells (6 ). We used additional markers (DCs: CD123, CD141, CD1C; monocytes: CD14, CD16) to create overlapping gates that comprehensively and evenly sample DCs and monocytes (6) .
To define subpopulations and identify useful markers for further isolation, we performed deep scRNA-seq using a modified Smart-Seq2 protocol (6), followed by sequencing of~1 million to 2 million paired-end reads per cell (7, 8) . Of 768 DCs and 372 monocytes initially profiled in the selected individual for discovering subsets, we focused on 742 DCs and 339 monocytes that passed quality control (QC) filters (6) with an average of 5326 unique genes detected per cell. In subsequent validation and characterization phases, we additionally profiled 1200 cells.
Unbiased classification of LIN
We defined six cell clusters within the LIN -
HLA-DR +

CD14
-population using unsupervised analysis that did not rely on known markers of DCs. Briefly, we identified 595 genes exhibiting high variability across single cells, reduced the dimensionality of these data with principal components analysis (PCA), and identified five significant PCs using a previously described permutation test (6, 9) . We used these PC loadings as input to t-distributed stochastic neighbor embedding (t-SNE) (10) for visualization, and clustered cells using a graph-based approach similar to one recently developed for mass cytometry data (6, 11) . We observed six clusters numbered DC1 to DC6 as follows: two clusters mapping closely to the well-established DC subsets, with cluster DC1 mapping to CD141 + DCs and cluster DC6 to pDCs (based on the post hoc overlap of transcript and surface marker expression); two clusters containing the CD1C + cDCs, cluster DC2 (CD1C_A) and cluster DC3 (CD1C_B); a cluster corresponding to the poorly characterized CD141 -CD1C -population, cluster DC4; and one cluster that does not correspond to any of the known blood DC subtypes, cluster DC5 (Fig. 1C and  fig. S1 ).
We identified 242 genes [area under curve (AUC) ≥ 0.85] that best classified cells into these six putative cell populations (Fig. 1D and fig.  S2A ; see tables S1 and S2 for a list of markers, including surface markers). Although cluster DC1 mapped most closely to CD141 + DCs, this commonly used CD141 (THBD/BDCA-3) marker was a poor discriminator for this cluster, being also expressed by cells captured in clusters DC5 and DC6 (pDCs) ( fig. S2B ). Because CLEC9A appeared to be a perfect discriminative surface marker for the DC1 cluster, we refer to this subset henceforth as CLEC9A + DCs. Clusters DC2 and DC3 mapped to CD1C + DCs. CD1C was the best and sole marker uniquely shared by both clusters. The DC4 cluster mapped to the CD141 -
CD1C
-population and was accurately delineated by FCGR3A/CD16. The DC5 cluster was best defined by the surface markers AXL and SIGLEC6. Finally, the DC6 cluster mapped to pDCs. However, several markers commonly used to identify pDCs (e.g., IL3RA/CD123, CLEC4C/CD303) were also expressed in the population defined by the DC5 cluster, leading us to define a new combination of markers that distinguish pDCs from the DC5 population. Altogether, we identified sets of discriminative markers that can be used in combination to isolate cell populations corresponding to known DC subsets (but with higher purity) as well as to previously uncharacterized subsets.
Two subpopulations within CD1C + DCs
The CD1C + DCs were distributed across two clusters with similar numbers of cells, which we termed CD1C_A (cluster DC2) and CD1C_B (cluster DC3). Comparing the two clusters, the CD1C_B cells were distinguished by their expression of a strong unique signature that includes acute and chronic inflammatory genes (12) (13) (14) such as CD14, S100A9, and S100A8, whereas CD1C_A cells were marked only by slightly higher levels of MHC class II genes ( Fig. 2A and table S3 ). We validated the presence of the two populations by prospective isolation based on newly identified markers, followed by scRNA-seq. To isolate these cells by flow sorting, we developed a panel incorporating surface markers derived from the set of uniquely expressed genes: FCGR2B/ CD32B for CD1C_A, and CD163 and CD36 for CD1C_B subsets (Fig. 2B) . scRNA-seq of prospectively isolated cells from each subset recapitulated the original split observed in CD1C + DCs (Fig. 2C) . Unlike monocytes and pDCs, both CD1C_A and CD1C_B subsets (isolated with the newly identified markers) were potent stimulators of naïve T cell proliferation (P < 0.05, paired t test), consistent with the known functional characteristics of cDCs (Fig. 2D) . Activation of both CD1C subsets with lipopolysaccharide (LPS), R848 (a TLR7/TLR8 agonist), and polyinosinepolycytidine [poly(I:C)] highlighted functional differences between these subsets ( fig. S3 and table S4), with CD1C_A secreting higher levels of the immune mediators CCL19, interleukin-10 (IL-10), IL-12B, and IL-18. Thus, scRNA-seq revealed unappreciated heterogeneity in this particular subset, leading to new hypotheses about the functions of CD1C + DCs.
Discovering monocyte subsets and their relationships to DC subsets
Some key genes known to be associated with monocytes were also expressed by CD1C_B (cluster DC3) and CD141 signature genes. Mono3 expresses a unique combination of genes that have the potential to affect cell cycle, differentiation, and trafficking (e.g., MXD1, CXCR1, CXCR2, VNN2) whereas Mono4 distinctively expressed a cytotoxic gene signature (e.g. PRF1, GNLY, CTSW ) resembling previously reported "natural killer dendritic cells," in addition to coexpressing Mono1 gene set (15) (16) (17) ( Fig. 3C and fig. S4B ). We conclude that the previously defined classical and nonclassical subtypes are contained in two distinct clusters (Mono1 and Mono2, respectively), but that the intermediate monocytes are far more heterogeneous than previously appreciated, being distributed across two known and two new clusters ( fig. S4A ).
All monocyte subtypes shared a signature that distinguishes them collectively from CD1C + DC (cluster DC2 and DC3), CLEC9A + DC (cluster DC1), and pDC (cluster DC6) populations (e.g., ITGAM/ CD11B, ITGB2/CD18, TLR2, and CLEC7A) (Fig. 3,  B and C, and fig. S4B ). Thus, despite coexpressing genes such as CD14 and S100A8, Mono1 and CD1C_B/DC3 cells were part of distinct clusters (Fig. 3, B and C) . CD1C + DCs (DC2 and DC3) expressed unique markers (e.g., CD1C, CLEC10A, FCER1A, FCGR2B, and CD1D) enriched for antigen processing (P < 2.66 × 10 ), and leukocyte activation (P < 1.14 × 10
) gene ontology (GO) terms (Fig. 3C and table S6) (6) . In contrast, Mono1 cells were enriched for defense response (P < 2.15 × 10 ), and chemotaxis (P < 6.77 × 10 −10 ) genes.
Finally, we interrogated the relationship between CD16-expressing CD141 -
CD1C
-cells (cluster DC4) and CD16 + monocytes (cluster Mono2). Although the two populations shared many genes (e.g., FCGR3A), they formed distinct clusters (Fig.  3B ) defined by a unique discriminative gene set ( Fig. 3C and tables S7 and S8). DC4 cells were enriched for type I interferon signaling pathway (P < 1.53 × 10 ) and response to virus (P < 4.77 × 10
) GO terms, whereas Mono2 cells were enriched for immune system process (P < 1.09 × 10
) and leukocyte migration (P < 3.57 × 10 −8 ) GO terms. Although we conclude that monocytes and DCs are distinct from each other in the steady state, our data do not address potential interconversion between cell fates or distinct ontogeny.
AXL + SIGLEC6
+ population and its relation to cDCs and pDCs As described above, a population emerged from the unbiased cluster analysis (cluster DC5; Fig. 1 ), defined by coexpression of unique markers (e.g., AXL, SIGLEC1, SIGLEC6, and CD22/SIGLEC2) (Fig. 4A, fig. S5A , and tables S1 and S2). Flow cytometry analysis of peripheral blood mononuclear cells (PBMCs) from 10 independent donors confirmed the existence of AXL + SIGLEC6 + cells ("AS DCs") within the original DC gate (Fig. 4B ) at a frequency of 2 to 3%, consistent with what was originally observed in the initial scRNA-seq analysis (30 of 768 DCs; Fig. 1C ). scRNA-seq profiling of prospectively sorted AS DCs (isolated with the gating strategy in Fig. 4B ) showed that the newly sorted cells clustered together with the original cluster ( Fig. 4C and fig.  S5B ), validating our enrichment strategy.
AS DCs exhibited a spectrum of states based on gene expression (Fig. 4D ) defined by cells enriched for a pDC-like signature (e.g., IL3RA, IGJ, NRP1, MZB1) and cells enriched for a cDClike signature (IFI30, ITGAX, LY86, GLIPR2, FGR, LYZ, ENTPD1). We validated this observation by flow cytometry, using the surface markers IL3RA/CD123 and ITGAX/CD11C that respectively correlated with pDC and cDC gene signatures (Fig. 4, B and D) . We exploited the combinatorial expression of AXL, SIGLEC6, CD123, and CD11C (at both mRNA and protein levels) to prospectively isolate the ends of this spectrum representing two putative AS DC subtypes (see gating strategy in Fig. 4B) , and further validated their identities by scRNA-seq (Fig. 4E and fig. S5 , C to F). Across all 10 individuals tested, the two AS DC subpopulations represented a very small fraction of the Lin -HLA-DR + populations (Fig. 4F) . Notably, lower levels of AXL and SIGLEC6 protein were associated with increased HLA-DR, CD11C, and CD1C, whereas higher levels of AXL and SIGLEC6 were associated with increased CD123, CD303, and CD141 and decreased HLA-DR (fig. S5, C to J). This latter relationship was also observed by t-SNE analysis of flow cytometry data, where a peninsula with graded expression of AS DCs was located at the base of the CD1C + DC cluster and adjacent to the pDC cluster (Fig. 4G) 
AS DCs
Because pDCs and AXL
DCs shared expression of many genes (Fig. 4 , D and E, and fig. S6A ), we assessed whether these cell types also shared functional properties. We found that the genes specifically expressed by pDCs, but not by AS DCs, were associated with the known biological properties of pDCs. This includes, for example, genes associated with pathogen sensing and induction of type I interferons (IRF7, TLR7, SLC15A4, and PACSIN1), secretion (e.g., DERL3, LAMP5, and SCAMP5), and the pDC master regulator transcription factor TCF4, along with its binding targets (e.g., SLA2, PTCRA, PTPRCAP) ( Fig. 5A and fig. S6A ) (18, 19) . In contrast, CD123 + CD11C -/lo AS DCs expressed cDC markers, including CD2, CX3CR1, CD33/SIGLEC3, CD5, and SIGLEC1/CD169, both at protein and mRNA levels ( Fig. 5A and fig. S6 , A to C). pDCs were also morphologically distinct from AS DCs. Both AS DC subsets possessed the same cerebriform nucleus and cytoplasmic features of cDCs ( To compare the functional properties of "pure" pDCs to AS DCs and cDCs, we used the markers identified in our study to isolate pure pDCs by excluding AS DCs, CLEC9A + DCs, CD1C + DCs, and monocytes by FACS. As expected, pure pDCs produced their hallmark cytokine, interferon-a (IFN-a) , while AS DCs produced negligible amounts of IFN-a upon Toll-like receptor 9 (TLR9) stimulation (P < 0.001; Fig. 5C ). In contrast, the CD123 lo CD11C
+ AS DC subset secreted IL-12p70 at similar levels to other cDCs, while pure pDCs and CD123 hi CD11C
-/lo AS DCs did not produce IL-12p70 (P < 0.01; Fig. 5C ). Other factors, such as IL-8, were produced at high levels by the CD123 + CD11C -/lo AS DC subset but not by pDCs CD11C, CD22, CD33, CD34, CD45RA, CD100, CD123, CD303, and HLA-DR (see Fig. 6 for CD100 hi CD34 int population). Overlay of populations defined by conventional flow cytometry gating on clusters derived by t-SNE analysis is shown in the legend.
(P < 0.001; fig. S6D ). Finally, pure pDCs induced undetectable or low levels of T cell proliferation in response to LPS or LPS + R848 stimulation, respectively (P < 0.05; Fig. 5D ). We conclude that "pure" IFN-a-producing pDCs (depleted of AS DCs) do not up-regulate CD86 ( fig. S6 , C and E), are diminished in their ability to induce T cell proliferation, and that contamination of AS DCs within the traditionally defined pDC gate is likely responsible for T cell stimulation activities measured in prior reports (18) (19) (20) .
AS DCs stimulate T cell proliferation and are present in tonsils
Because AS DCs expressed the costimulator CD86 and components of antigen presentation, we hypothesized that they could stimulate T cell proliferation ( fig. S6 , A, C, and E). Strikingly, both AS DC subtypes were potent stimulators of allogeneic CD4 + and CD8 + T cell proliferation, unlike pDCs (P < 0.01), and were marginally superior to CD1C
+ and CLEC9A + DCs (Fig. 5E ). Similar to other DCs, AS DCs expressed CLA and CD62L but not CCR7 protein ( fig. S6F ), suggesting potential homing to peripheral tissue such as skin and lymph node from the circulation. Because CD123 + pDCs were observed in the T cell area of the human tonsil (21), we evaluated whether CD123 + AS DCs were also present by staining human tonsils with antibodies to CD123 and AXL. We found AS DCs adjacent to CD3 + T cells, admixed with CD123 + AXL -pDCs (Fig. 5F ). 
HLA-DR
+ fraction (Fig. 5F ). Thus, AS DCs are able to stimulate T cells and are present in the T cell zones of tonsils. S7, A and B) . Cells in cluster 6 expressed genes associated with hematopoiesis, DC progenitors, and genes essential for DC development (e.g., SATB1, RUNX2, KIT, HLX, ID2) (22-25) and were marked by high expression of the cell surface protein SEMA4D (CD100). We therefore hypothesized that cluster 6 could represent a progenitor population.
Identification of circulating
To assess the progenitor potential of this compartment, we cultured FACS-purified CD11C -
CD123
cells with MS5 stromal cells and cytokines that induce DC differentiation (6), based on a published human DC progenitor differentiation assay (26) . After several days in culture, the cells were evaluated by flow cytometry, using a panel of antibodies that identify pDCs and CD1C + and CLEC9A + DCs (6), and by scRNA-Seq profiling of CD45 + immune cells for a more comprehensive assessment. For comparison, under the same conditions, we monitored the differentiation potential of isolated pDCs, CD1C + and CLEC9A + DCs, and AS DC subtypes (see fig. S7 , C and D).
After 7 days of culture, cells isolated from the CD11C -
-gate gave rise to CLEC9A + and CD1C + DCs but not pDCs, according to flow cytometry and scRNA-seq analyses (Fig. 6B) . We narrowed down the search for the progenitor cells to the CD45RA + CD39 -CD100 + pool of cells based on the unique cluster-6 marker CD100/SEMA4D ( fig. S7B) , along with candidate markers that we tested [based on DC progenitors in the bone marrow (CD45RA) and tissue DC (CD39) markers] (Fig. 6C, fig. S5J, fig. S6, B and F, and fig. S7 , B to H). After iteratively testing each sorted population for differentiation potential, we discovered that only the CD100 hi CD34 int cells generated CLEC9A + and CD1C + DCs (Fig. 6C and fig. S7F ). scRNA-seq of CD100 hi CD34
int cells mapped these cells to the original cluster 6, including the expression of the same DC differentiation and progenitor function genes ( fig. S7B) .
We validated the existence of CD100 (Fig. 6D ). These cells were morphologically primitive, possessing high nuclear-to-cytoplasmic ratios and circular or indented nuclei (Fig. 6D) , in contrast to AS DCs, pDCs, and CD1C + and CLEC9A + DCs (Fig. 5B) . Although CD100 
Differentiation potential of AS DCs
When we seeded cultures with pDCs and CD1C + and CLEC9A + DCs, we found that they generally retained the same phenotype throughout the differentiation assay (Fig. 6F and fig. S7, I S7, I and J)]. After 7 days in culture, we observed cells with high levels of CD1C (frequency 40 to 50%, n = 6 donors) and rare cells with surface CLEC9A and CADM1 (0.5 to 0.8%) expression (Fig. 6F) , irrespective of the FLT3L concentration used (Fig. 6F) or whether the culture was seeded with either of the two AS DC subpopulations representing both ends of the spectrum (fig. S7K) . Notably, both AS DCs at day 0 and the cells differentiated from AS DCs did not express BATF3 (a transcription factor required for terminal differentiation of CLEC9A + DCs), CADM1, or XCR1, which are key CLEC9A + DC discriminative markers ( fig. S8C ) or with hematopoietic progenitors (e.g., SOX4 and CLEC11A). Collectively, our analysis suggests that although BPDCN malignant cells express some key B cell markers, they are most closely related to pDCs.
Discussion
DCs and monocytes are defined according to a combination of molecular markers, functional properties, and ontogeny (39) . However, it remains unclear whether the expression of existing markers tracks with the more complex internal states of cells.
To address this question, we determined the states of blood DCs/monocytes through comprehensive profiling of gene expression at single-cell resolution, empirically inferred cell subtypes, identified optimal surface markers for purifying the hypothesized cell subtypes, and showed that prospectively purified cell types corresponded to inferred subtypes based on scRNA-seq. Our study has generated a more accurate taxonomy that includes six DC subtypes and four monocyte subtypes, as well as a circulating, dividing progenitor of cDCs. Previous studies classified human blood DCs into one pDC and two cDC populations. Our study identifies six DC populations: DC1 corresponds to the cross-presenting CD141/BDCA-3 + cDC1, which is best marked by CLEC9A; DC2 and DC3 correspond to new subdivisions of the CD1C/BDCA-1 + cDC2; DC4 corresponds to CD1C -CD141 -CD11C + DC, which is best marked by CD16 and shares signatures with monocytes; DC5 is a unique DC subtype, AS DCs; and DC6 corresponds to the interferon-producing pDC, purer than previously identified pDC populations defined by standard markers (CD123, CD303/BDCA-2) and contaminated with AS DCs. In the process of addressing how DCs resemble monocytes, we also identified four monocyte subtypes: the two known ones, as well as two new ones that have not been functionally characterized. Although DC2/3 and DC4 shared an expression signature with monocytes, our data do not suggest how they acquired these shared modules (common precursor, interconversion, or independent convergence). Finally, we derived specific expression signatures for each DC and monocyte subtype, including transcription factors, cytokines, and cytokine receptors ( fig. S9 , A to F, and table S10), providing a resource for further understanding of subtype functions and ontogeny.
The CD1C/BDCA-1 + DC subdivision (DC2 and DC3) is further supported by parallel observations in their murine CD11b + DC homologs (40-43), which comprise an Esam lo subset with higher expression of myeloid genes such as CD14 and potent cytokine production, and an Esam hi subset with better MHC class II-dependent priming of CD4 + T cells (40, 41) . AS DCs, which were found within the pDC gate, formed a continuum between pDCs and CD1C + DCs ( fig. S5 , C to F). Consistent with this observation, AS DCs were able to transition toward the CD1C + DC state in vitro (with <1% of differentiated AS DCs phenotypically resembling CLEC9A + DCs, which could be contaminants). However, because AS DCs (at both ends of the continuum) morphologically resemble cDCs and are able to stimulate T cell proliferation, yet do not proliferate themselves, they seem less likely to serve as a progenitor that generates cDCs and are more likely to be a functional DC variant that can be modulated to resemble CD1C + DCs. Although AS DCs most closely resemble CD1C + cDCs in basic functional properties and expression signatures, they are likely to have distinct functions because they localize to the T cell zone of tonsils and express several lectins, which recognize diverse glycans, and AXL, which interacts with apoptotic cells and Zika virus (44) (45) (46) .
An unresolved question concerns the importance of AS DCs sharing an expression signature with pDCs. Consistent with our findings that AS DCs are found in the traditional pDC flow cytometry gate, a recently described human CD2 hi pDC subset (20) appears to correspond to AS DCs based on expression of CD2, AXL, CX3CR1, LYZ, and CD86 ( fig. S6C) , localization to tonsils, and a similar ability to trigger naïve T cell proliferation. Furthermore, a murine study identified noncanonical CX3CR1 + CD8a
+ cDCs (nc-cDCs), which express pDC and cDC signatures (e.g., CX3CR1, CD11c, and MHCII), do not produce IFN-a, and activate T cell proliferation (47, 48) . Interestingly, pDCs and nc-cDCs require E2-2/TCF4 to develop, and reduced levels of E2-2 lead to higher ID2 and expression of cDC genes (18, 47, 48) . Consistent with this finding, we observed E2-2/TCF4 expression in human pDCs (Fig. 5A) , with decreasing levels of E2-2/TCF4 and increasing levels of ID2 as AS DCs transition to CD1C + DCs ( fig. S5 , C to F). These findings suggest that AS DCs are similar to human CD2 hi pDCs and murine nc-cDCs. The discovery of AS DCs led us to update the strategy for isolating pDCs. When we removed AS DCs from pDCs isolated with standard markers (e.g., CD123 and CD303), the resulting pDCs were highly attenuated in their ability to induce T cell proliferation and produce T cell stimulatory ligands (e.g., IL-12), consistent with reports that found several markers splitting pDCs into those that stimulate or do not stimulate T cells (18, 20, (49) (50) (51) (52) . We thus propose that our purer pDC population corresponds more closely to the "natural interferon-producing cells (IPCs)" (21, 53) . These cells also appear to share more properties with plasma B cells than DCs, as indicated by morphology, higher expression of endoplasmic reticulum secretory machinery, known rearrangement at the Ig (immunoglobulin) locus, and expression of B cell-related transcripts. We also found that BPDCN cells share the pDC signature as well as additional B cell genes (e.g., IGLL1, IGLL5, and TCL1A). We conclude that even though pure pDCs fall into the MHC II-expressing gate, they have markers, gene signatures, and functions distinct from those of cDCs.
In contrast to AS DCs, the CD100 hi CD34 int cells appear to be cDC progenitors, judging by their primitive morphology, absence of cDC functions and signatures, and potent ability to proliferate and generate a large and equal number of CD1C + DCs and CLEC9A + DCs within 7 days of culture. The recently identified human pre-cDC (24) (25) (26) (27) (28) , which has proliferative capacity and differentiates into CD1C + and CD141 + DCs, appears to have some functional and phenotypical similarities to our CD100 hi CD34 int progenitors, even though our cells appear to be morphologically more primitive and lack the expression of CD116 and CD135, which were previously reported as markers (24 int progenitors provides a well-defined cell type for generating DCs in vitro and for therapeutic targeting. Our new strategy for isolating pure pDCs, combined with the knowledge that the functions of contaminating AS DCs were incorrectly attributed to pDCs, should lead to more definitive annotation of pDC functions with implications for their therapeutic application (54) (55) (56) . More generally, our use of the DC atlas to understand BPDCN cells illustrates how single-cell analysis can pinpoint relationships of diseased cells to healthy cells. Finally, some susceptibility genes identified in human genetics association studies are expressed in the DCs and monocyte subsets defined in this study, suggesting new potential roles in disease (fig. S10, A and B, and table S11, A to C).
Using single-cell transcriptome profiling, we deconvoluted admixtures of cell types (e.g., pDCs, "intermediate" monocytes, cDC progenitors), revealed rare cell types (e.g., AS DCs), and elucidated complex relationships between cell types (e.g., spectrum of states for AS DCs)-thus addressing limitations in the existing classification that relies on a small number of markers (39) . Nonetheless, some DC/monocyte subtypes were likely missed because they do not express MHC class II at rest, can only be defined by non-RNA molecules, are distinguished by low-abundance transcripts, or are only present during inflammation, disease, or within tissues. To build a comprehensive immune cell atlas, future studies will need to address these challenges as well as localize these cell types within lymphoid and nonlymphoid tissues.
Materials and methods
Study subjects
The study was performed in accordance with protocols approved by the institutional review board at Partners (Brigham and Women's Hospital, Massachusetts General Hospital, Dana-Farber Cancer Institute; Boston, USA) and Broad Institute (USA), as well as the Newcastle upon Tyne Hospitals (UK) Research Ethics Committee. All patients provided written informed consent for the genetic research studies and molecular testing. Healthy donors were recruited from the Boston-based PhenoGenetic project, a resource of healthy subjects that are recontactable by genotype (57) , and the Newcastle community. Individuals were excluded if they had a history of cancer, allergies, inflammatory disease, autoimmune disease, chronic metabolic disorders, or infectious disorders. All healthy donors were nonsmokers, had a normal BMI and normal blood pressure, and were between 25 and 40 years of age.
Cell isolation, flow cytometry staining, cell sorting, and analysis For profiling of healthy cells, PBMCs were isolated from fresh blood within 2 hours of collection, using Ficoll-Paque density gradient centrifugation as described (58) . Single-cell suspensions were stained per manufacturer recommendations with different panels of antibodies (table S12) designed to enrich for certain population for single-cell sorting and single-cell RNA sequencing (scRNA-seq) (6) . Flow cytometry and FACS sorting of PBMCs was performed on a BD Fortessa or BD FACS Fusion instrument, and data analyzed using FlowJov10.1. Single cells were sorted into 96-well full-skirted Eppendorf plates chilled to 4°C, preprepared with lysis buffer consisting of 10 ml of TCL buffer (Qiagen) supplemented with 1% b-mercaptoethanol. Single-cell lysates were sealed, vortexed, spun down at 300 g at 4°C for 1 min, immediately placed on dry ice, and transferred for storage at -80°C. Tonsil was mechanically disrupted to obtain single-cell suspension.
Single-cell RNA sequencing Smart-Seq2 protocol was performed on single sorted cells as described (7, 8) , with some modifications (6) . Note that some of these single cells were excluded from the analysis after applying QC filters and analytically confirming cell type (6).
Single-cell RNA sequencing analyses
Raw sequencing data were processed as described (59) (see tables S13 to S16 for cell identities that accompany raw data and gene expression matrices). Briefly, short sequencing reads were aligned to the UCSC hg19 transcriptome. These alignments were used to estimate transcriptomic alignment rates and were also used as input in RSEM v 1.2.1 to quantify gene expression levels (transcripts per million; TPM) for all UCSC hg19 genes in all samples. We filtered out low-quality cells from our data set based on a threshold for the number of genes detected (a minimum of 3000 unique genes per cell for cells sequenced at HiSeq depth, and 2000 unique genes per cell for cells sequenced at MiSeq depth). All genes that were not detected in at least 0.5% of all our single cells were discarded, leaving 21,581 genes for all further analyses. Data were log-transformed [log(TPM + 1)] for all downstream analyses, most of which were performed using the R software package Seurat (https://github.com/satijalab/seurat; http://satijalab. org/seurat/). See (6) for further details, including R script used to generate clusters.
DC differentiation assay on MS5 stromal cells DC differentiation assay was performed as described (23-25) with minor adaptation. Briefly, 1 × 10 4 purified progenitors, DCs, and monocyte subsets were cultured in 96-well flat-bottom plates layered with 4 × 10 4 murine MS5 stromal cells (DSMZ, Germany) in the presence of human FLT3 ligand (FL; 100 ng/ml; Miltenyi Biotec), recombinant human SCF (20 ng/ml; R&D Systems), and recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) (10 ng/ml; Peprotech). MS5 stromal cells were seeded 24 hours prior to coculture. Growth factors were replenished on day 3 of culture. Cells were in culture for up to 7 days prior to harvesting by physical dissociation on ice. Cells were then stained on ice either for flow cytometry analysis (see output panel in table S12) or single-cell index sorting of CD45 + cells for scRNA-seq of culture output analysis.
Cytokine production measurements
Purified subsets were cultured at 5 × 10 3 cells per well in 96-well round-bottom plates in the presence of LPS (100 ng/ml; Invivogen) and ODN2395 (1 mM; Invivogen) or ODN5328 (ODN2395 control, 1 mM; Invivogen), or in the presence of LPS, poly(I:C) (25 mg/ml; Invivogen), and R848 (2.5 mg/ml; Enzo Life Sciences). Culture supernatants were harvested after 24 hours and analyzed using a multiplexed cytokine assay (ProcartaPlex, eBioscience), or by leveraging the 92 inflammatory-related protein biomarker panel and four controls provided by Olink Proteomics (Uppsala, Sweden) (6).
Assessing T cell stimulatory potential DC, monocyte, and progenitor subsets were purified from peripheral blood of healthy donors by FACS sorting (BD FACS Fusion; see table S12 for sorting panels and antibodies). For T cell stimulatory potential, purified DCs, monocytes, AXL + SIGLEC6 + subsets, and progenitor subset were cultured at cell density of 5 × 10 4 per well. All purified cell subsets were matured with LPS (100 ng/ml, Sigma) and R848 (2.5 mg/ml, Invivogen), or with just LPS (100 ng/ml), for 24 hours prior to coculture with 5 × 10 5 CFSElabeled allogeneic unfractionated CD3
+ T cells at a 1:10 DC:T cell ratio. T cell proliferation was assessed by measuring CFSE dilution on day 5 of culture.
Cytospin and immunostaining
Cytospin of FACS-purified cells was prepared as described (60) using Shandon Cytospin 4 (Thermo Scientific). Giemsa-Wright staining was performed using Advia S60 (Siemens) and imaged using Axioimager.Z2 microscope with Axiovision softwarev4.8 (Carl Zeiss, Germany). Human tonsil paraffin sections were immunostained with the antibodies anti-AXL (MM0098-2N33, Abcam), CD123 (BR4MS, Leica Biosystems) and CD3 (LN10, Leica Biosystems) using a Ventana Benchmark XT instrument.
Monitoring cell proliferation
PBMCs were labeled with Cell Trace Violet (CTV, Life Technologies) according to manufacturer's protocol. CTV-labeled FACS-purified progenitors and DC subsets were cultured on murine MS5 stromal cells as described above and analyzed on day 5 to assess proliferation measured by CTV dilution.
